With Shifting Iran Rhetoric Following US Elections, Trump Leaves Mideast in Limbo About Path AheadNovember 15, 2026
Undercover FBI Agent: “They Cooked Him Alive in a 55 Gallon Drum” | Official PreviewNovember 14, 2026
Oliver Thomas on October 22, 2026 11:51 am Uranium names keep pushing higher—supply still tight into 2026. Reply
Jennifer Y. Martin on October 22, 2026 11:53 am Silver leverage is strong here; beta cuts both ways though. Reply
Liam Smith on October 22, 2026 11:54 am Exploration results look promising, but permitting will be the key risk. Reply
John Rodriguez on October 22, 2026 11:54 am If AISC keeps dropping, this becomes investable for me. Reply
Isabella T. Hernandez on October 22, 2026 11:56 am Uranium names keep pushing higher—supply still tight into 2026. Reply
John Davis on October 22, 2026 11:56 am Uranium names keep pushing higher—supply still tight into 2026. Reply
Lucas Martinez on October 22, 2026 11:57 am Uranium names keep pushing higher—supply still tight into 2026. Reply
Elijah Hernandez on October 22, 2026 11:58 am Nice to see insider buying—usually a good signal in this space. Reply
Patricia V. Taylor on October 22, 2026 12:00 pm Interesting update on The Origins of Pharma. Curious how the grades will trend next quarter. Reply
Ava Martin on October 22, 2026 12:00 pm The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Elizabeth Martinez on October 22, 2026 12:02 pm Interesting update on The Origins of Pharma. Curious how the grades will trend next quarter. Reply
Emma Martinez on October 22, 2026 12:03 pm Silver leverage is strong here; beta cuts both ways though. Reply
Amelia Thompson on October 22, 2026 12:04 pm Uranium names keep pushing higher—supply still tight into 2026. Reply
Linda L. Rodriguez on October 22, 2026 12:05 pm Exploration results look promising, but permitting will be the key risk. Reply
Lucas Thomas on October 22, 2026 12:05 pm The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Emma Lee on October 22, 2026 12:05 pm Interesting update on The Origins of Pharma. Curious how the grades will trend next quarter. Reply
By JackCarrUSA
By JackCarrUSA
By JackCarrUSA
31 Comments
Uranium names keep pushing higher—supply still tight into 2026.
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
If AISC keeps dropping, this becomes investable for me.
Uranium names keep pushing higher—supply still tight into 2026.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Interesting update on The Origins of Pharma. Curious how the grades will trend next quarter.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Interesting update on The Origins of Pharma. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Silver leverage is strong here; beta cuts both ways though.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Interesting update on The Origins of Pharma. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.